NASDAQ:GERN - Geron Stock Price, Price Target & More

$4.09 +0.08 (+2.00 %)

(As of 04/24/2018 12:36 PM ET)

Previous Close$4.01

Today's Range$4.02 - $4.28

52-Week Range$1.74 - $6.68

Volume3.38 million shs

Average Volume6.19 million shs

Market Capitalization$608.88 million

P/E Ratio-22.61

Dividend YieldN/A

Beta2.26

About Geron (NASDAQ:GERN)

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Janssen is engaged in the development of Imetelstat with two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity.

Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:GERN

CUSIP37416310

Webwww.geron.com

Phone650-473-7700

Debt

Debt-to-Equity RatioN/A

Current Ratio14.74%

Quick Ratio14.74%

Price-To-Earnings

Trailing P/E Ratio-22.61

Forward P/E Ratio409.00

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.07 million

Price / Sales614.07

Cash FlowN/A

Price / CashN/A

Book Value$0.65 per share

Price / Book6.29

Profitability

EPS (Most Recent Fiscal Year)($0.18)

Net Income$-27,910,000.00

Net Margins-2,621.22%

Return on Equity-25.25%

Return on Assets-23.38%

Miscellaneous

Employees18

Outstanding Shares160,650,000

How to Become a New Pot Stock Millionaire

Geron (NASDAQ:GERN) Frequently Asked Questions

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) issued its quarterly earnings data on Friday, March, 16th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01. The biopharmaceutical company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.41 million. Geron had a negative net margin of 2,621.22% and a negative return on equity of 25.25%. Geron's revenue for the quarter was up 103.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.05) EPS. View Geron's Earnings History.

When is Geron's next earnings date?

Geron is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Geron.

What price target have analysts set for GERN?

4 analysts have issued 12-month price objectives for Geron's stock. Their forecasts range from $4.00 to $7.00. On average, they anticipate Geron's stock price to reach $5.50 in the next twelve months. View Analyst Ratings for Geron.

Are investors shorting Geron?

Geron saw a increase in short interest in March. As of March 29th, there was short interest totalling 44,086,309 shares, an increase of 19.1% from the March 15th total of 37,028,235 shares. Based on an average daily volume of 23,019,985 shares, the short-interest ratio is presently 1.9 days. Approximately 27.6% of the shares of the company are short sold.

Who are some of Geron's key competitors?

Some companies that are related to Geron include Puma Biotechnology (PBYI), Horizon Pharma (HZNP), Heron Therapeutics (HRTX), Global Blood Therapeutics (GBT), Portola Pharmaceuticals (PTLA), AnaptysBio (ANAB), Medicines (MDCO), Motif (MTFB), Intercept Pharmaceuticals (ICPT), Corcept Therapeutics (CORT), Esperion Therapeutics (ESPR), Spectrum Pharmaceuticals (SPPI), Arena Pharmaceuticals (ARNA), Aimmune Therapeutics (AIMT) and Cambrex (CBM).

Who are Geron's key executives?

Geron's management team includes the folowing people:

Hoyoung Huh Ph.D., Independent Chairman of the Board (Age 48)
John A. Scarlett M.D., President, Chief Executive Officer, Director (Age 66)
Olivia K. Bloom, Chief Financial Officer, Executive Vice President - Finance, Treasurer (Age 46)
Stephen N. Rosenfield J.D., Executive Vice President, General Counsel and Corporate Secretary (Age 62)
Andrew J. Grethlein Ph.D., Executive Vice President - Development and Technical Operations (Age 50)
Melissa A. Kelly Behrs, Executive Vice President - Business Development and Portfolio and Alliance Management (Age 51)
Susan M. Molineaux Ph.D., Director (Age 63)
Daniel Mark Bradbury, Independent Director (Age 56)
Karin Eastham CPA, Independent Director (Age 67)
V. Bryan Lawlis Jr. Ph.D., Independent Director (Age 65)

Has Geron been receiving favorable news coverage?

News headlines about GERN stock have been trending somewhat negative on Tuesday, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Geron earned a news impact score of -0.01 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 43.99 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $4.07.

How big of a company is Geron?

Geron has a market capitalization of $608.88 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,910,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Geron employs 18 workers across the globe.

How can I contact Geron?

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]

MarketBeat Community Rating for Geron (GERN)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		237 (Vote Outperform)
Underperform Votes:		184 (Vote Underperform)
Total Votes:		421

MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Geron (NASDAQ:GERN) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

4 Wall Street analysts have issued ratings and price targets for Geron in the last 12 months. Their average twelve-month price target is $5.50, suggesting that the stock has a possible upside of 34.47%. The high price target for GERN is $7.00 and the low price target for GERN is $4.00. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.50	2.50	2.50	2.50
Ratings Breakdown:	0 Sell Rating(s) 2 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$5.50	$5.50	$4.1667	$4.1667
Price Target Upside:	34.47% upside	29.41% upside	96.54% upside	45.18% upside

Geron (NASDAQ:GERN) Consensus Price Target History

Price Target History for Geron (NASDAQ:GERN)

Geron (NASDAQ:GERN) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/19/2018	Piper Jaffray	Reiterated Rating	Buy	$7.00	High
3/18/2018	Stifel Nicolaus	Boost Price Target	Hold -> Hold	$2.50 -> $4.00	High
11/3/2017	Needham & Company LLC	Reiterated Rating	Hold		N/A
7/4/2017	FBR & Co	Reiterated Rating	Buy		Medium
9/20/2016	BTIG Research	Reiterated Rating	Neutral		N/A

(Data available from 4/24/2016 forward)

Geron (NASDAQ:GERN) Earnings History and Estimates Chart

Earnings by Quarter for Geron (NASDAQ:GERN)

Geron (NASDAQ:GERN) Earnings Estimates

Current Year EPS Consensus Estimate: $0.01 EPS
Next Year EPS Consensus Estimate: $-0.18 EPS

Geron (NASDAQ GERN) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/8/2018
3/16/2018	Q4 2017	($0.04)	($0.05)	$0.41 million	$0.19 million	View	Listen
11/1/2017	Q3 2017	($0.05)	($0.04)	$0.40 million	$0.16 million	View	N/A
8/9/2017	Q2 2017	($0.05)	($0.04)	$0.38 million	$0.17 million	View	N/A
5/9/2017	Q1 2017	($0.05)	($0.05)	$0.27 million	$0.54 million	View	N/A
3/1/2017	Q416	($0.06)	($0.05)	$0.18 million	$0.09 million	View	Listen
11/3/2016	Q316	($0.06)	($0.02)	$0.22 million	$5.10 million	View	Listen
8/3/2016	Q216	($0.07)	($0.05)	$0.38 million	$0.21 million	View	Listen
5/5/2016	Q116	($0.06)	($0.06)	$0.26 million	$0.74 million	View	Listen
2/25/2016	Q415	($0.05)	($0.05)	$0.32 million	$0.22 million	View	Listen
11/5/2015	Q315	$0.11	$0.17	$17.87 million	$35.40 million	View	Listen
8/5/2015	Q2 15	($0.06)	($0.05)	$0.40 million	$0.25 million	View	N/A
4/30/2015	Q1	($0.06)	($0.06)	$0.32 million	$0.54 million	View	N/A
3/3/2015	Q4	$0.17	($0.06)	$35.35 million	$0.18 million	View	Listen
11/5/2014	Q314	($0.06)	($0.06)	$0.28 million	$0.16 million	View	N/A
8/11/2014	Q214	($0.06)	($0.06)	$0.22 million	$0.34 million	View	Listen
5/1/2014	Q114	($0.06)	($0.06)	$0.35 million	$0.47 million	View	Listen
3/27/2014		($0.06)	($0.07)			View	N/A
3/17/2014	Q413	($0.07)	($0.07)	$0.35 million	$0.23 million	View	Listen
11/7/2013	Q313	($0.06)	($0.06)	$0.49 million	$0.18 million	View	Listen
8/8/2013	Q2 2013	($0.07)	($0.07)	$0.50 million	$0.11 million	View	Listen
4/25/2013	Q1 2013	($0.08)	($0.09)	$0.71 million	$0.77 million	View	Listen
3/12/2013	Q4 2012	($0.14)	($0.12)	$0.50 million	$0.69 million	View	Listen
10/30/2012	Q312	($0.14)	($0.13)	$0.38 million	$0.6360 million	View	N/A
7/31/2012		($0.15)	($0.14)			View	N/A
5/2/2012		($0.18)	($0.15)			View	N/A
3/7/2012	Q4 2011	($0.20)	($0.22)			View	N/A
11/3/2011		($0.18)	($0.16)			View	N/A
7/28/2011		($0.18)	($0.17)			View	N/A
4/27/2011		($0.19)	($0.20)			View	N/A
2/24/2011		($0.19)	($0.39)			View	N/A
10/28/2010	Q3 2010	($0.20)	($0.19)			View	N/A
7/29/2010	Q2 2010	($0.19)	($0.18)			View	N/A
4/28/2010	Q1 2010	($0.20)	($0.18)			View	N/A
2/25/2010	Q4 2009	($0.17)	($0.20)			View	N/A
10/29/2009	Q3 2009	($0.21)	($0.17)			View	N/A
7/30/2009	Q2 2009	($0.19)	($0.23)			View	N/A
4/29/2009	Q1 2009	($0.20)	($0.20)			View	N/A
2/26/2009	Q4 2008	($0.21)	($0.22)			View	N/A
10/30/2008	Q3 2008	($0.20)	($0.22)			View	N/A
7/30/2008	Q2 2008	($0.20)	($0.17)			View	N/A
4/29/2008	Q1 2008	($0.18)	($0.18)			View	N/A
2/27/2008	Q4 2007	($0.12)	($0.22)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Geron (NASDAQ:GERN) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Geron (NASDAQ GERN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 36.89%

Insider Trading History for Geron (NASDAQ:GERN)

Institutional Ownership by Quarter for Geron (NASDAQ:GERN)

Geron (NASDAQ GERN) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/29/2015	Olivia Kyusuk Bloom	CFO	Sell	2,380	$3.84	$9,139.20
3/18/2015	Thomas Hofstaetter	Director	Sell	70,000	$4.10	$287,000.00
5/29/2014	Melissa Kelly Behrs	EVP	Sell	4,826	$2.10	$10,134.60
5/29/2014	Olivia Kyusuk Bloom	CFO	Sell	3,379	$2.10	$7,095.90
5/9/2014	Daniel Bradbury	Director	Buy	142,776	$1.75	$249,858.00	142,776
4/1/2014	Melissa Kelly Behrs	EVP	Sell	12,310	$2.13	$26,220.30	147,841
4/1/2014	Olivia Kyusuk Bloom	CFO	Sell	7,435	$2.13	$15,836.55	85,347
4/1/2013	John A Scarlett	CEO	Buy	50,000	$1.03	$51,500.00

(Data available from 1/1/2013 forward)

Geron (NASDAQ GERN) News Headlines

Source:

Date	Headline
	Geron (GERN) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 21 at 7:06 AM
	Geron (GERN) Given "Buy" Rating at FBR & Co www.americanbankingnews.com - April 19 at 10:12 PM
	Johnson & Johnson Reaffirms Geron's Imetelstat As Lead Oncology Pipeline Drug seekingalpha.com - April 19 at 5:40 PM
	Geron (GERN) Downgraded to Hold at Zacks Investment Research www.americanbankingnews.com - April 19 at 12:49 PM
	Geron (GERN) Rating Increased to Buy at Zacks Investment Research www.americanbankingnews.com - April 18 at 12:50 PM
	Why Geron Corporation's Stock Is Heading Higher Today www.fool.com - April 18 at 8:16 AM
	Geron Faces A Make-Or-Break Catalyst This Week seekingalpha.com - April 17 at 5:54 PM
	Why Geron Corporation's Stock Is Heading Higher Today finance.yahoo.com - April 17 at 5:54 PM
	Why Geron Doesn't Pass Our Screens seekingalpha.com - April 16 at 8:16 AM
	Why Is Geron (GERN) Up 10.6% Since Its Last Earnings Report? finance.yahoo.com - April 16 at 8:16 AM
	Here's Why Geron Stock Surged More Than 90% in 6 Months finance.yahoo.com - April 13 at 5:32 PM
	Rounds Report: Geron Rallied While FDA's New Guidance Created Tailwinds For Individualized Medicine Innovators seekingalpha.com - April 13 at 8:19 AM
	Today’s Research Reports on Stocks to Watch: Geron Corp. and Rigel Pharmaceuticals finance.yahoo.com - April 13 at 8:19 AM
	Why Geron Corporation Stock Is on the Rise Today finance.yahoo.com - April 12 at 3:21 PM
	Geron Co. (GERN) Short Interest Update www.americanbankingnews.com - April 12 at 2:18 AM
	Brokerages Anticipate Geron Co. (GERN) to Announce -$0.04 EPS www.americanbankingnews.com - April 12 at 1:13 AM
	BioSci Rounds Report: Regenxbio Surged, Geron Trading Reversed And Dexcom G6 Approved seekingalpha.com - April 10 at 8:27 AM
	Geron Corp.: It's Hard Enough To Get A Drug To Market Without The Questionable Bearish Arguments seekingalpha.com - April 10 at 8:27 AM
	Geron Corp.: It's Hard Enough To Get A Drug To Market Without The Misinformed Attacks seekingalpha.com - April 9 at 5:21 PM
	Geron (GERN) Downgraded by Zacks Investment Research www.americanbankingnews.com - April 7 at 4:58 PM
	BioSci Rounds Report: Intercept Making A Comeback, Improving FDA Policy Can Help Geron seekingalpha.com - April 6 at 5:41 PM
	Geron: The Better, The Worse And The Uglier seekingalpha.com - April 6 at 8:27 AM
	BioSci Research On Geron (Part II): Evaluating The Hidden Value Of The Myelofibrosis Franchise seekingalpha.com - April 5 at 5:17 PM
	GERON INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Geron Corporation To Contact The Firm finance.yahoo.com - April 5 at 5:17 PM
	Your Daily Pharma Scoop: Geron Update, Rigel Setback, Bio-Path Results seekingalpha.com - April 4 at 8:21 AM
	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Geron Corporation finance.yahoo.com - April 3 at 5:35 PM
	Why Geron Corporation Stock Is Falling Today finance.yahoo.com - April 2 at 5:27 PM
	Geron Co. (GERN) Receives Average Rating of "Hold" from Analysts www.americanbankingnews.com - April 1 at 1:54 AM
	BidaskClub Downgrades Geron (GERN) to Buy www.americanbankingnews.com - March 30 at 1:06 PM
	Here's Why Geron's Stock Is Cratering Today www.nasdaq.com - March 30 at 8:23 AM
	IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Geron Corporation finance.yahoo.com - March 29 at 5:30 PM
	SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Geron Corporation (GERN) finance.yahoo.com - March 28 at 5:18 PM
	Here's Why Geron's Stock Is Cratering Today finance.yahoo.com - March 28 at 5:18 PM
	EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Geron Corporation - GERN finance.yahoo.com - March 28 at 5:18 PM
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Geron Corporation - GERN www.prnewswire.com - March 27 at 6:19 PM
	Why Geron Corporation Stock Is Crashing Today finance.yahoo.com - March 27 at 5:14 PM
	Why Twitter, Overstock.com, and Geron Slumped Today finance.yahoo.com - March 27 at 5:14 PM
	Geron slips 7% premarket on bearish Feuerstein article seekingalpha.com - March 27 at 8:13 AM
	Geron (GERN) Rating Increased to Hold at BidaskClub www.americanbankingnews.com - March 26 at 5:58 PM
	Geron Co. (GERN) Expected to Announce Earnings of -$0.04 Per Share www.americanbankingnews.com - March 26 at 3:24 AM
	Why Geron Corp. Is Rallying 10% Today finance.yahoo.com - March 23 at 5:42 PM
	Is Geron Corporation Stock Still a Strong Buy? finance.yahoo.com - March 22 at 5:36 PM
	Exploring Geron’s Financial Performance finance.yahoo.com - March 21 at 5:38 PM
	A Close Look at Geron’s Imetelstat finance.yahoo.com - March 21 at 5:38 PM
	Why Geron Corporation Stock Is Up Big Again Today finance.yahoo.com - March 21 at 5:38 PM
	Geron to Present at the Needham Healthcare Conference finance.yahoo.com - March 21 at 8:48 AM
	Health Care Sector Update for 03/19/2018: CDTX,MDWD,GERN,REGN - Nasdaq www.nasdaq.com - March 20 at 8:28 AM
	Edited Transcript of GERN earnings conference call or presentation 19-Mar-18 12:30pm GMT finance.yahoo.com - March 20 at 8:28 AM
	Stifel Nicolaus Analysts Give Geron (GERN) a $4.00 Price Target www.americanbankingnews.com - March 19 at 5:34 PM
	Geron (GERN) Q4 2017 Earnings Conference Call Transcript finance.yahoo.com - March 19 at 5:18 PM

Geron (NASDAQ:GERN) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Geron (NASDAQ:GERN) Income Statement, Balance Sheet and Cash Flow Statement

Geron (NASDAQ GERN) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff